- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01827839
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Coquitlam, British Columbia, Canada, V3K 3P4
- GSK Investigational Site
-
-
Quebec
-
Pointe-Claire, Quebec, Canada, H9R 4S3
- GSK Investigational Site
-
-
-
-
-
Barnaul, Russian Federation, 656056
- GSK Investigational Site
-
Ekaterinburg, Russian Federation, 620137
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with a physician-documented history of HZ.
- Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- A male or female aged 50 years or older at the time of the first vaccination.
- Written informed consent obtained from the subject.
Female subjects of non-childbearing potential may be enrolled in the study.
- Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion Criteria:
- Active Herpes Zoster infection (a case is considered no more active when all lesions have at least turned to crusts).
- Use of any investigational or non-registered product other than the study vaccine/product within 30 days preceding the first dose of study vaccine/product, or planned use during the study period.
- Chronic administration (defined as > 14 consecutive days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, a prednisone dose of <20 mg/day, or equivalent, is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
- Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.
- Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
- Previous vaccination against VZV or HZ and/or planned administration during the study of an HZ vaccine other than the study vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine/product.
Acute disease and/or fever at the time of enrolment.
- Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route for recording temperature in this study will be oral.
- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
- Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe.
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive precautions before Month 4 (i.e. 2 months after the last dose of study vaccine).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HZ Group
Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.
|
2 doses administered intramuscularly in deltoid region of non-dominant arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA
Time Frame: At Month 3
|
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for anti-gE [4x97 milli-international units per milliliter (mIU/mL)]; For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. |
At Month 3
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Time Frame: Within 7 days (Day 0-6) after each vaccine dose and across doses
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
|
Within 7 days (Day 0-6) after each vaccine dose and across doses
|
Number of Days With Solicited Local Symptoms
Time Frame: Within 7 days (Day 0-6) after each vaccine dose
|
The number of days with any local symptoms during the solicited post-vaccination period.
|
Within 7 days (Day 0-6) after each vaccine dose
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Time Frame: Within 7 days (Day 0-6) after each vaccine dose and across doses
|
Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature [defined as oral temperature equal to or above 37.5 degrees Celsius (°C)].
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 symptom = symptom that prevented normal activity.
Grade 3 temperature = temperature > 39.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
|
Within 7 days (Day 0-6) after each vaccine dose and across doses
|
Number of Days With Solicited General Symptoms
Time Frame: Within 7 days (Day 0-6) after each vaccine dose
|
The number of days with general symptoms during the solicited post-vaccination period.
|
Within 7 days (Day 0-6) after each vaccine dose
|
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
Time Frame: Within 30 days (Days 0-29) after each vaccination
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Grade 3 AE = an AE which prevented normal, everyday activities.
Related = AE assessed by the investigator as related to the vaccination.
|
Within 30 days (Days 0-29) after each vaccination
|
Number of Subjects With Any Serious Adverse Events (SAEs)
Time Frame: From first vaccination up to 30 days post last vaccination
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
From first vaccination up to 30 days post last vaccination
|
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
Time Frame: From first vaccination up to 30 days post last vaccination
|
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
|
From first vaccination up to 30 days post last vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-gE Antibody Concentrations
Time Frame: At Month 0 and at Month 3
|
Anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).
The outcome was assessed in each of the following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, in terms of antibody concentrations.
|
At Month 0 and at Month 3
|
Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value
Time Frame: At Month 0 and at Month 3
|
The cut-off value was 97 mIU/mL.
|
At Month 0 and at Month 3
|
Number of Subjects With SAEs
Time Frame: Starting after 30 days post last vaccination until study end (i.e. Month 14)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
Starting after 30 days post last vaccination until study end (i.e. Month 14)
|
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
Time Frame: Starting after 30 days post last vaccination until study end (i.e. Month 14)
|
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
|
Starting after 30 days post last vaccination until study end (i.e. Month 14)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116796
- 2012-003643-30 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Informed Consent Form
Information identifier: 116796Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 116796Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 116796Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 116796Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 116796Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 116796Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 116796Information comments: For additional information about this study please refer to the GSK Clinical Study Register
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Herpes Zoster
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineCanada, Spain, Korea, Republic of, United Kingdom, France, Czechia
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Estonia, Canada
-
Ohio State UniversityCompletedHerpes Zoster DiseaseUnited States
-
Merck Sharp & Dohme LLCCompletedHerpes Zoster | Herpes Zoster-related Complications
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Canada, Belgium
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
-
Tanta UniversityNot yet recruitingAcute Herpes Zoster Pain Managment
-
Northwestern UniversityBausch & Lomb IncorporatedTerminatedHerpes Zoster KeratitisUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Centrexion TherapeuticsTerminatedAcute-onset Herpes Zoster PainAustralia
Clinical Trials on Herpes Zoster vaccine (GSK1437173A)
-
GlaxoSmithKlineCompletedHerpes ZosterGermany, Czechia, Sweden, Netherlands
-
GlaxoSmithKlineCompletedHerpes ZosterUnited States, Australia, Spain, Finland, Germany, Japan, Taiwan, Sweden, Korea, Republic of, Brazil, Mexico, Canada, Italy, France, Czechia, Estonia, Hong Kong, United Kingdom
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedHerpes ZosterUnited States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
-
GlaxoSmithKlineCompletedHerpes ZosterGermany, Czechia, Sweden
-
GlaxoSmithKlineCompletedHerpes ZosterUnited States, Australia, Germany, Spain, Finland, Japan, Taiwan, Sweden, Korea, Republic of, Hong Kong, Mexico, Canada, Italy, France, Brazil, Estonia, United Kingdom, Czechia
-
GlaxoSmithKlineCompletedHerpes ZosterSpain, Taiwan, Italy, Canada, Belgium, Finland, Korea, Republic of, Panama, Czechia
-
GlaxoSmithKlineCompletedHerpes ZosterUnited States, Australia, France, Spain, Finland, Estonia, Russian Federation, Taiwan, Belgium, Korea, Republic of, Czechia, Germany, Hong Kong, Israel, Turkey, United Kingdom, Greece, Romania, Netherlands, Italy, South Africa, Ca... and more
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom